{"id":"everolimus-afinitor-tablets","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Stomatitis/mouth ulcers"},{"rate":"30-40","effect":"Infections"},{"rate":"30-40","effect":"Fatigue"},{"rate":"25-35","effect":"Diarrhea"},{"rate":"25-35","effect":"Rash"},{"rate":"20-30","effect":"Anemia"},{"rate":"15-25","effect":"Hyperglycemia"},{"rate":"15-25","effect":"Hyperlipidemia"},{"rate":"1-5","effect":"Pneumonitis"}]},"_chembl":{"chemblId":"CHEMBL1908360","moleculeType":"Small molecule","molecularWeight":"958.24"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Everolimus is an mTOR inhibitor that blocks the mTORC1 signaling pathway, which regulates cell cycle progression and protein synthesis. By suppressing this pathway, it reduces tumor cell proliferation and angiogenesis. It is used in oncology to treat various cancers where mTOR pathway activation drives tumor growth.","oneSentence":"Everolimus inhibits mTOR (mammalian target of rapamycin), a protein kinase that controls cell growth and proliferation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:46:29.234Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced renal cell carcinoma"},{"name":"Advanced pancreatic neuroendocrine tumors"},{"name":"Hormone receptor-positive, HER2-negative advanced breast cancer"},{"name":"Subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex"}]},"trialDetails":[{"nctId":"NCT06943755","phase":"PHASE2, PHASE3","title":"Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors","status":"RECRUITING","sponsor":"Exelixis","startDate":"2025-07-21","conditions":"Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)","enrollment":440},{"nctId":"NCT07435584","phase":"PHASE1, PHASE2","title":"Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE)","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-03-01","conditions":"Colorectal Cancer","enrollment":38},{"nctId":"NCT05476939","phase":"PHASE3","title":"Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2022-09-29","conditions":"Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Midline Glioma, H3K27-altered","enrollment":433},{"nctId":"NCT02813135","phase":"PHASE1, PHASE2","title":"European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2016-08-03","conditions":"Pediatric Cancer","enrollment":472},{"nctId":"NCT01797523","phase":"PHASE2","title":"A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-10-07","conditions":"Endometrial Cancer","enrollment":62},{"nctId":"NCT07218575","phase":"PHASE2, PHASE3","title":"Double-Blind Trial of Everolimus for Improving Social Abilities in PTEN Germline Mutations","status":"NOT_YET_RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2026-04","conditions":"Cowden's Disease, Cowden's Syndrome, Lhermitte-Duclos Disease","enrollment":60},{"nctId":"NCT06680921","phase":"PHASE3","title":"A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)","status":"RECRUITING","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2024-11-14","conditions":"Locally Advanced or Metastatic Breast Cancer","enrollment":460},{"nctId":"NCT01734512","phase":"PHASE2","title":"PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2012-12-13","conditions":"Pediatric Recurrent Progressive Low-grade Gliomas, Pediatric Progressive Low-grade Gliomas","enrollment":65},{"nctId":"NCT01805271","phase":"PHASE3","title":"Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2013-03","conditions":"Primary Non-metastatic Breast Cancer, Who Remain Disease-free","enrollment":1278},{"nctId":"NCT04195750","phase":"PHASE3","title":"A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-27","conditions":"Carcinoma, Renal Cell","enrollment":755},{"nctId":"NCT02991807","phase":"PHASE1, PHASE2","title":"RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2017-06-12","conditions":"PTEN Gene Mutation, PTEN Hamartoma Tumor Syndrome","enrollment":46},{"nctId":"NCT02216786","phase":"PHASE2","title":"A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer","status":"COMPLETED","sponsor":"Queen Mary University of London","startDate":"2014-01-16","conditions":"Estrogen Receptor Positive Breast Cancer","enrollment":333},{"nctId":"NCT03154281","phase":"PHASE1","title":"Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast","status":"COMPLETED","sponsor":"Avera McKennan Hospital & University Health Center","startDate":"2017-07-26","conditions":"Breast Cancer, Ovarian Cancer","enrollment":14},{"nctId":"NCT01698918","phase":"PHASE2","title":"Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-03-07","conditions":"Hormone Receptor Positive Breast Cancer","enrollment":202},{"nctId":"NCT03355794","phase":"PHASE1","title":"A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2017-11-14","conditions":"Diffuse Intrinsic Pontine Glioma, Malignant Glioma of Brain, High Grade Glioma","enrollment":19},{"nctId":"NCT03163667","phase":"PHASE2","title":"CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)","status":"COMPLETED","sponsor":"Calithera Biosciences, Inc","startDate":"2017-09-06","conditions":"Clear Cell Renal Cell Carcinoma","enrollment":69},{"nctId":"NCT01668784","phase":"PHASE3","title":"Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-10-09","conditions":"Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma","enrollment":821},{"nctId":"NCT05490095","phase":"PHASE1","title":"Randomized Crossover of SVG101(Dispersible Tab. of Everolimus) and Afinitor 5mg in Healthy Adults","status":"COMPLETED","sponsor":"Sovargen","startDate":"2021-07-23","conditions":"Pharmacokinetics","enrollment":26},{"nctId":"NCT01263951","phase":"PHASE2","title":"Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone","status":"UNKNOWN","sponsor":"Thomas Jefferson University","startDate":"2010-11","conditions":"Differentiated Thyroid Cancer","enrollment":35},{"nctId":"NCT00936858","phase":"PHASE2","title":"RAD001 for Patients With Radioiodine Refractory Thyroid Cancer","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2009-07","conditions":"Thyroid Cancer","enrollment":50},{"nctId":"NCT03525834","phase":"PHASE4","title":"Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-11-09","conditions":"Renal Angiomyolipoma","enrollment":40},{"nctId":"NCT02732119","phase":"PHASE1, PHASE2","title":"Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-06-14","conditions":"Breast Cancer","enrollment":104},{"nctId":"NCT01865747","phase":"PHASE3","title":"A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma","status":"COMPLETED","sponsor":"Exelixis","startDate":"2013-06","conditions":"Renal Cell Carcinoma","enrollment":658},{"nctId":"NCT01929642","phase":"PHASE2","title":"Rapalogues for Autism Phenotype in TSC: A Feasibility Study","status":"COMPLETED","sponsor":"Hugo W. Moser Research Institute at Kennedy Krieger, Inc.","startDate":"2013-07","conditions":"Tuberous Sclerosis Complex, Self-injury, Autism","enrollment":3},{"nctId":"NCT01088048","phase":"PHASE1","title":"Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-03-25","conditions":"Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma","enrollment":241},{"nctId":"NCT01482156","phase":"PHASE1","title":"Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-01","conditions":"Advanced Solid Tumors, Metastatic Breast Cancer, Metastatic Renal Cell Carcinoma","enrollment":46},{"nctId":"NCT00434174","phase":"PHASE1","title":"Safety of Everolimus and Pemetrexed in Lung Cancer Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-12","conditions":"Non Small Cell Lung Cancer","enrollment":48},{"nctId":"NCT02511639","phase":"PHASE3","title":"Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients","status":"COMPLETED","sponsor":"Istituto Oncologico Veneto IRCCS","startDate":"2014-07-30","conditions":"Breast Cancer Metastatic","enrollment":110},{"nctId":"NCT02113800","phase":"PHASE2","title":"Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2015-08","conditions":"Poorly Differentiated Malignant Neuroendocrine Carcinoma, Neuroendocrine Carcinoma, Grade 3, Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3","enrollment":40},{"nctId":"NCT01627067","phase":"PHASE2","title":"Exemestane-RAD001-Metformin","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-09","conditions":"Breast Cancer","enrollment":23},{"nctId":"NCT01596140","phase":"PHASE1","title":"Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-12-18","conditions":"Advanced Cancer, Solid Tumor","enrollment":27},{"nctId":"NCT00419159","phase":"PHASE2","title":"Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-12","conditions":"Colorectal Cancer","enrollment":199},{"nctId":"NCT01661283","phase":"PHASE2","title":"SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors","status":"COMPLETED","sponsor":"Sarcoma Alliance for Research through Collaboration","startDate":"2012-09","conditions":"Malignant Peripheral Nerve Sheath Tumors, MPNST, Sarcoma","enrollment":25},{"nctId":"NCT00968253","phase":"PHASE1, PHASE2","title":"RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-11","conditions":"Leukemia, Acute Lymphocytic Leukemia","enrollment":24},{"nctId":"NCT01595009","phase":"PHASE4","title":"An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-04-27","conditions":"Neuroendocrine Tumors","enrollment":246},{"nctId":"NCT02560012","phase":"PHASE2","title":"Personalized Targeted Inhibitors Treatment in Renal Cell Cancer","status":"TERMINATED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2016-01-04","conditions":"Carcinoma, Renal Cell","enrollment":4},{"nctId":"NCT01797120","phase":"PHASE2","title":"Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI","status":"COMPLETED","sponsor":"PrECOG, LLC.","startDate":"2013-05-31","conditions":"Metastatic Breast Cancer","enrollment":131},{"nctId":"NCT01107509","phase":"NA","title":"Pilot Study of Neo-Adjuvant Everolimus to Treat Advanced Renal Cell Carcinoma - Analysis of Biomarkers","status":"COMPLETED","sponsor":"St. Joseph's Healthcare Hamilton","startDate":"2010-10-01","conditions":"Carcinoma, Renal Cell","enrollment":20},{"nctId":"NCT02338570","phase":"PHASE4","title":"Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE)","status":"TERMINATED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2015-07","conditions":"Renal Cell Carcinoma","enrollment":31},{"nctId":"NCT01289912","phase":"PHASE2","title":"Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC)","status":"COMPLETED","sponsor":"Mustafa Sahin","startDate":"2011-01","conditions":"Tuberous Sclerosis Complex","enrollment":52},{"nctId":"NCT00814788","phase":"PHASE2","title":"Bicalutamide With or Without Everolimus in Treating Patients With Recurrent or Metastatic Prostate Cancer","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2008-12","conditions":"Prostate Cancer","enrollment":24},{"nctId":"NCT02248571","phase":"PHASE4","title":"Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab","status":"COMPLETED","sponsor":"iOMEDICO AG","startDate":"2014-08","conditions":"Breast Cancer Recurrent, HER2/Neu-negative Carcinoma of Breast, Hormone Receptor Positive Malignant Neoplasm of Breast","enrollment":85},{"nctId":"NCT01419639","phase":"PHASE2","title":"Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2011-10","conditions":"Neurofibromatosis Type II","enrollment":10},{"nctId":"NCT01642732","phase":"PHASE1","title":"Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer","status":"TERMINATED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2012-10","conditions":"Prostate Cancer","enrollment":1},{"nctId":"NCT01070316","phase":"PHASE1, PHASE2","title":"Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2010-01","conditions":"Epilepsy, Tuberous Sclerosis Complex","enrollment":20},{"nctId":"NCT00790400","phase":"PHASE3","title":"Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-04","conditions":"Tuberous Sclerosis Complex (TSC), Lymphangioleiomyomatosis (LAM)","enrollment":118},{"nctId":"NCT01637090","phase":"PHASE2","title":"Everolimus in Treating Cutaneous T-cell Lymphoma","status":"TERMINATED","sponsor":"Adam Lerner","startDate":"2012-06","conditions":"Cutaneous T-Cell Lymphoma","enrollment":3},{"nctId":"NCT02013089","phase":"NA","title":"A Pilot Study of Genomic Sequencing Guided Individualized Therapy in Gastrointestinal Cancers, GITIC Study","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2013-12","conditions":"Gastrointestinal Cancers","enrollment":50},{"nctId":"NCT02404051","phase":"PHASE3","title":"Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Consorzio Oncotech","startDate":"2015-12","conditions":"Metastatic Breast Cancer, Breast Cancer, Hormone Receptor Positive Tumor","enrollment":745},{"nctId":"NCT01997255","phase":"PHASE2","title":"Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS)","status":"WITHDRAWN","sponsor":"Baylor College of Medicine","startDate":"2014-04","conditions":"Sturge Weber Syndrome","enrollment":""},{"nctId":"NCT01466231","phase":"PHASE2","title":"Everolimus in Refractory Testicular Germ Cell Cancer","status":"COMPLETED","sponsor":"National Cancer Institute, Slovakia","startDate":"2011-11","conditions":"Germ Cell Tumor","enrollment":15},{"nctId":"NCT01889420","phase":"PHASE1","title":"Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"New Mexico Cancer Research Alliance","startDate":"2014-07","conditions":"Multiple Myeloma in Relapse","enrollment":1},{"nctId":"NCT01804374","phase":"PHASE2","title":"Phase II Open Label, Non-randomized Study of Sorafenib and Everolimus in Relapsed and Non-resectable Osteosarcoma","status":"COMPLETED","sponsor":"Italian Sarcoma Group","startDate":"2011-06","conditions":"Metastatic Osteosarcoma, Relapsed Osteosarcoma","enrollment":38},{"nctId":"NCT01408004","phase":"PHASE2","title":"Rotating Pazopanib and Everolimus to Avoid Resistance","status":"COMPLETED","sponsor":"Netherlands Working Group on Immunotherapy of Oncology","startDate":"2011-11","conditions":"Clear Cell Renal Carcinoma","enrollment":101},{"nctId":"NCT01793636","phase":"PHASE2","title":"A Study Comparing AZD2014 vs Everolimus in Patients With Metastatic Renal Cancer","status":"TERMINATED","sponsor":"Queen Mary University of London","startDate":"2013-02","conditions":"Metastatic Clear Cell Renal Carcinoma","enrollment":49},{"nctId":"NCT02025712","phase":"PHASE2","title":"Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Organisation for Oncology and Translational Research","startDate":"","conditions":"Hormone Receptor Positive Malignant Neoplasm of Breast","enrollment":35},{"nctId":"NCT01175096","phase":"PHASE1, PHASE2","title":"Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor","status":"UNKNOWN","sponsor":"Guangdong Provincial People's Hospital","startDate":"2010-07","conditions":"Neuroendocrine Tumors, Carcinoid Tumor","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Everolimus (Afinitor) tablets","genericName":"Everolimus (Afinitor) tablets","companyName":"Exelixis","companyId":"exelixis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Everolimus inhibits mTOR (mammalian target of rapamycin), a protein kinase that controls cell growth and proliferation. Used for Advanced renal cell carcinoma, Advanced pancreatic neuroendocrine tumors, Hormone receptor-positive, HER2-negative advanced breast cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}